Literature DB >> 28054315

The Missing Link in the Diagnostic Pathway of Prostate Cancer.

Arne Vidar Tind Wøyen1, Gergely Laczkó2, Søren Høyer3, Laszlo Hegyi4.   

Abstract

Prostate cancer is one of the most common cancers in the Western world. It is among the leading causes of cancer related death. While its incidence and survival increased significantly during the last few decades in Denmark, the mortality rate did not change for patients younger than 80 year old. Development of new techniques, such as multiparametric MRI, helps to increase the accuracy of diagnosis. However, a missing link in the diagnostic pathway may result in mistreatment if an acinar adenocarcinoma of prostate is transformed into a neuroendocrine phenotype such as small cell carcinoma.

Entities:  

Keywords:  Adenocarcinoma; Immunohistochemistry; Prostatic carcinoma; Small cell carcinoma

Mesh:

Year:  2017        PMID: 28054315     DOI: 10.1007/s12253-016-0183-1

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  7 in total

Review 1.  Unusual and underappreciated: small cell carcinoma of the prostate.

Authors:  Jeffrey S Palmgren; Saumil S Karavadia; Mark R Wakefield
Journal:  Semin Oncol       Date:  2007-02       Impact factor: 4.929

2.  Treatment outcomes of small cell carcinoma of the prostate: a single-center study.

Authors:  Philippe E Spiess; Curtis A Pettaway; Funda Vakar-Lopez; Wassim Kassouf; Xuemei Wang; Joseph E Busby; Kim-Anh Do; Rajayogesh Davuluri; Nizar M Tannir
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

Review 3.  Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives.

Authors:  Matteo Santoni; Alessandro Conti; Luciano Burattini; Rossana Berardi; Marina Scarpelli; Liang Cheng; Antonio Lopez-Beltran; Stefano Cascinu; Rodolfo Montironi
Journal:  Biochim Biophys Acta       Date:  2014-11-04

4.  Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.

Authors:  T Burchardt; M Burchardt; M W Chen; Y Cao; A de la Taille; A Shabsigh; O Hayek; T Dorai; R Buttyan
Journal:  J Urol       Date:  1999-11       Impact factor: 7.450

5.  p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.

Authors:  Zhen Li; Yin Sun; Xufeng Chen; Jill Squires; Behdokht Nowroozizadeh; Chaozhao Liang; Jiaoti Huang
Journal:  Mol Cancer Res       Date:  2014-12-15       Impact factor: 5.852

Review 6.  Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.

Authors:  Panagiotis J Vlachostergios; Christos N Papandreou
Journal:  Front Oncol       Date:  2015-02-02       Impact factor: 6.244

Review 7.  The many faces of neuroendocrine differentiation in prostate cancer progression.

Authors:  Stéphane Terry; Himisha Beltran
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

  7 in total
  1 in total

1.  Anticancer Activity of Ganoderic Acid DM: Current Status and Future Perspective.

Authors:  John Matthew Bryant; Mollie Bouchard; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2017-12-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.